Planet Labs PBC (PL)
Valuation Overview•Is Planet Labs PBC Overvalued or Undervalued?
Commands a premium valuation multiple over its peers, likely pricing in superior execution.
Fragile underlying quality score of 32/100; weak margins or elevated debt leverage warrant caution.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Mixed fundamental profile with offsetting strengths and weaknesses.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
PL struggles with subpar profitability and pressured margins. This is paired with a moderately leveraged but stable balance sheet.
The company is driving exceptional top-line expansion (17.2% 3Y CAGR) paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (-31.9%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $94.2M | +25.9% | +17.2% | +22.1% | — | |
| EBITDA | -$33.6M | — | -21.7% | — | — | |
| Net Income | -$138.9M | -100.4% | -15.1% | — | — | |
| EPS (Diluted) | $-0.40 | -90.5% | — | — | — | |
| Free Cash Flow | -$1.9M | +198.3% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 55.5% | 54.8% | 50.1% | 38.0% |
| Operating Margin | -31.9% | -51.8% | -69.0% | -76.2% |
| Net Margin | -111.2% | -64.8% | -76.7% | -89.3% |
| FCF Margin | 14.1% | -15.8% | -27.3% | -32.4% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.04 | $-0.03 | +28.2% | ||
| Q1'26 | $-0.05 | $-0.48 | -916.7% | ||
| Q4'25 | $-0.03 | $-0.19 | -467.3% | ||
| Q3'25 | $-0.03 | $-0.03 | +0.0% | ||
| Q2'25 | $-0.05 | $-0.04 | +20.0% | ||
| Q1'25 | $-0.02 | $-0.08 | -300.0% | ||
| Q4'24 | $-0.04 | $-0.02 | +50.0% | ||
| Q3'24 | $-0.06 | $-0.06 | +0.0% |
Total return is +452.4% (1Y), outperforming the benchmark by +427.5%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +38.3% | +29.0% | — |
| 1Y | +452.4% | +427.5% | — |
| 3YCAGR | +107.7% | +88.2% | — |
| 5YCAGR | +23.4% | +10.9% | — |
| 10YCAGR | +11.0% | -2.6% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Planet Labs PBC (PL) valuation, health, and returns.
Planet Labs PBC is estimated to be fair under our discounted cash flow framework. relative multiples indicate the stock is Limited: Expensive versus peers compared to industry peers. trading near fair value (DCF: $23.45)
Planet Labs PBC has multiple valuation anchors: DCF Intrinsic Value: $23.45 | Peer Relative Fair Value: $9.03 | Wall Street Analyst Target: $40.86 (implying +44.7% upside). A convergence of these signals offers higher conviction.
Planet Labs PBC displays weak financial health with a composite quality score of 32/100, supported by a Altman Z-Score of 3.9 (safe zone), Piotroski F-Score of 2/9, Return on Invested Capital (ROIC) of -18.8%.
Planet Labs PBC does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Planet Labs PBC's current growth trajectory is Accelerating. The company achieved +25.9% 1Y revenue growth and -90.5% 1Y EPS growth, compared to its 3Y revenue CAGR of +17.2%.
Wall Street consensus is Buy based on 22 analysts, beating EPS expectations in 58% of recent quarters with a 1-quarter streak. The consensus price target represents a +44.7% change from current levels.
Investment risks for Planet Labs PBC include: -45.1% 1-year max drawdown, high beta (2.50x market volatility). Volatility risk is characterized by a beta of 2.50x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.